These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 15737519)

  • 1. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
    Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
    Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent.
    Tellier G; Brunton SA; Nusrat R
    South Med J; 2005 Sep; 98(9):863-8. PubMed ID: 16217977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis.
    Roos K; Tellier G; Baz M; Leroy B; Rangaraju M
    J Infect; 2005 Apr; 50(3):210-20. PubMed ID: 15780415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of interfering bacteria in the nasopharynx following antimicrobial therapy of acute maxillary sinusitis with telithromycin or amoxicillin-clavulanate.
    Brook I; Hausfeld JN
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4793-4. PubMed ID: 16251334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE; Brown S; Felmingham D
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of telithromycin and azithromycin on nasopharyngeal bacterial flora in patients with acute maxillary sinusitis.
    Brook I; Hausfeld JN
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):442-5. PubMed ID: 16618915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
    Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
    Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid.
    Brook I; Foote PA; Hausfeld JN
    Int J Antimicrob Agents; 2005 Nov; 26(5):416-9. PubMed ID: 16226017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents.
    Ling TK; Lee CC
    Chemotherapy; 2005 Jul; 51(4):182-5. PubMed ID: 15980628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
    Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
    Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004).
    Blasi F; Farrell DJ; Dubreuil L
    Diagn Microbiol Infect Dis; 2009 Mar; 63(3):302-8. PubMed ID: 19135821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin: the first ketolide antimicrobial.
    Nguyen M; Chung EP
    Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis.
    Desrosiers M; Ferguson B; Klossek JM; Drugeon H; Mösges R
    Curr Med Res Opin; 2008 Jun; 24(6):1691-702. PubMed ID: 18559163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.